169 related articles for article (PubMed ID: 32171300)
1. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.
Tabata M; Tsubaki M; Takeda T; Tateishi K; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
BMC Complement Med Ther; 2020 Mar; 20(1):84. PubMed ID: 32171300
[TBL] [Abstract][Full Text] [Related]
2. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.
Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
Leuk Res; 2014 Jan; 38(1):121-30. PubMed ID: 24239173
[TBL] [Abstract][Full Text] [Related]
3. [Wnt5a modulates vincristine resistance through PI3K/Akt/GSK3β signaling pathway in human ovarian carcinoma SKOV3/VCR cells].
Wu FL; Chen HL; Hu XW; Liang LY; Xu WL
Sheng Li Xue Bao; 2019 Jun; 71(3):415-423. PubMed ID: 31218332
[TBL] [Abstract][Full Text] [Related]
4. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
Chao CC
FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
[TBL] [Abstract][Full Text] [Related]
5. AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2019 Feb; 39(2):609-617. PubMed ID: 30711936
[TBL] [Abstract][Full Text] [Related]
6. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.
Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Imano M; Satou T; Nishida S
Lab Invest; 2019 Jan; 99(1):72-84. PubMed ID: 30353128
[TBL] [Abstract][Full Text] [Related]
8. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
[TBL] [Abstract][Full Text] [Related]
9. Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cells.
Tsubaki M; Takeda T; Matsuda T; Kishimoto K; Tanaka R; Tsurushima K; Ishizaka T; Nishida S
Clin Exp Med; 2023 Sep; 23(5):1597-1607. PubMed ID: 36451049
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
11. CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-κB pathway in Burkitt lymphoma.
Takeda T; Tsubak M; Genno S; Matsuda T; Yamamoto Y; Ueda E; Imano M; Satou T; Nishida S
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214335
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of multidrug resistance in feline lymphoma cells.
Okai Y; Nakamura N; Matsushiro H; Kato H; Setoguchi A; Yazawa M; Okuda M; Watari T; Hasegawa A; Tsujimoto H
Am J Vet Res; 2000 Sep; 61(9):1122-7. PubMed ID: 10976746
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.
Tsubaki M; Takeda T; Ogawa N; Sakamoto K; Shimaoka H; Fujita A; Itoh T; Imano M; Ishizaka T; Satou T; Nishida S
Leuk Res; 2015 Apr; 39(4):445-52. PubMed ID: 25726084
[TBL] [Abstract][Full Text] [Related]
14. 5'-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells.
Li D; Gale RP; Liu Y; Lei B; Wang Y; Diao D; Zhang M
Leuk Res; 2017 Jul; 58():23-30. PubMed ID: 28380403
[TBL] [Abstract][Full Text] [Related]
15. Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.
Zyada MM
Med Oncol; 2011 Dec; 28(4):1565-9. PubMed ID: 20524087
[TBL] [Abstract][Full Text] [Related]
16. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells.
Zhu CY; Lv YP; Yan DF; Gao FL
Asian Pac J Cancer Prev; 2013; 14(11):6757-60. PubMed ID: 24377601
[TBL] [Abstract][Full Text] [Related]
18. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
19. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
20. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
